Valuation: Rekah Pharmaceutical Industry Ltd.

Market Cap 116M 11.64B 37.1M 33.26M 30.61M 27.67M 51.79M 3.52B 52.78M 364M 146M 1.85B 139M 136M 5.84B P/E 2024
24.5x
P/E 2025 -6.91x
Enterprise Value 244M 24.44B 77.89M 69.82M 64.26M 58.09M 109M 7.4B 111M 764M 307M 3.89B 292M 286M 12.27B EV / Sales 2024
0.87x
EV / Sales 2025 0.84x
Free-Float
17.21%
Yield 2024 *
-
Yield 2025 -
25/08 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
01/06 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
30/03 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/11 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
01/09/25 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
30/05/25 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
31/03/25 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
26/11/24 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
29/08/24 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
28/05/24 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
27/03/24 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
28/11/23 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
01/09/23 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
1 week-1.35%
Current month-8.85%
1 month-8.93%
3 months-6.59%
6 months-11.23%
Current year-6.76%
1 week 1,012
Extreme 1012
1,050
1 month 1,012
Extreme 1012
1,209
Current year 1,006
Extreme 1006
1,348
1 year 1,006
Extreme 1006
1,348
3 years 1,006
Extreme 1006
1,679
5 years 1,006
Extreme 1006
2,566
10 years 1,006
Extreme 1006
4,076
Manager TitleAgeSince
Chief Executive Officer 82 24/08/1993
Director of Finance/CFO 46 01/11/2018
President 80 28/06/2010
Director TitleAgeSince
Chairman 82 25/06/2010
Director/Board Member 80 -
Chairman 80 15/04/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.35%-13.04%-38.26% 37.43M
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +1.68%+2.20%+41.69%+72.83% 417.69B
Weighted average by Cap. +1.28%+3.04%+53.35%+100.42%

Financials

2024 2025
Net sales 322M 32.17B 103M 91.89M 84.57M 76.45M 143M 9.73B 146M 1.01B 404M 5.12B 385M 377M 16.15B 301M 30.1B 95.91M 85.97M 79.12M 71.53M 134M 9.11B 136M 941M 378M 4.79B 360M 352M 15.11B
Net income 6.21M 621M 1.98M 1.77M 1.63M 1.47M 2.76M 188M 2.81M 19.41M 7.8M 98.74M 7.42M 7.26M 312M -18.07M -1.81B -5.76M -5.16M -4.75M -4.3M -8.04M -547M -8.19M -56.52M -22.71M -288M -21.61M -21.15M -907M
Net Debt 127M 12.71B 40.5M 36.3M 33.41M 30.2M 56.53M 3.84B 57.61M 397M 160M 2.02B 152M 149M 6.38B 128M 12.8B 40.79M 36.56M 33.65M 30.42M 56.94M 3.87B 58.03M 400M 161M 2.04B 153M 150M 6.43B
Projected Income Statement - Annual - Rekah Pharmaceutical Industry Ltd.
Logo Rekah Pharmaceutical Industry Ltd.
Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
Employees
390
Date Price Change Volume
30/10/26 ILA 1,020.00 0.00% 10
29/10/26 ILA 1,020.00 0.00% 758
28/10/26 ILA 1,020.00 0.00% 10
26/10/26 ILA 1,020.00 -0.58% 1,100
23/10/26 ILA 1,026.00 -0.77% 2,831
  1. Stock Market
  2. Stocks
  3. REKA Stock